Spark's planned price for Luxturna gene therapy for rare blindness too high: ICER
(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.
from Reuters: Health News http://reut.rs/2mlDPpe
http://bit.ly/2zwRqiM